Raymond James & Associates Exelixis, Inc. Call Options Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $3,488 - $4,632	-200 Reduced 0.68%	29,000 $30,000
Q1 2022 May 11, 2022	SELL	$17.03 - $22.67 $11,921 - $15,869	-700 Reduced 2.34%	29,200 $88,000
Q2 2021 Aug 11, 2021	SELL	$17.95 - $25.56 $66,415 - $94,572	-3,700 Reduced 11.01%	29,900 $79,000
Q2 2020 Jul 28, 2020	SELL	$16.46 - $27.42 $16,460 - $27,420	-1,000 Reduced 2.89%	33,600 $67,000
Q1 2020 Apr 21, 2020	BUY	$14.46 - $21.8 $111,342 - $167,860	7,700 Added 28.62%	34,600 $59,000
Q3 2019 Nov 07, 2019	SELL	$17.68 - $22.65 $1.07 Million - $1.37 Million	-60,700 Reduced 69.29%	26,900 $16,000
Q2 2019 Aug 06, 2019	SELL	$18.93 - $24.75 $550,863 - $720,225	-29,100 Reduced 24.94%	87,600 $87,000
Q1 2019 May 06, 2019	BUY	$19.6 - $24.76 $1.72 Million - $2.18 Million	87,900 Added 305.21%	116,700 $245,000
Q4 2018 Feb 11, 2019	SELL	$13.65 - $21.8 $9,555 - $15,260	-700 Reduced 2.37%	28,800 $101,000
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $468,165 - $660,800	29,500 New	29,500 $116,000

468

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.